Search

Despite advanced delivery methods, many cannabis beverages underperform because they prioritize pharmaceutical efficacy over crucial beverage formulation elements like flavor, mouthfeel, and stability, leading to poor consumer retention. Successful brands must adopt the flavor chemistry and preservation best practices from the conventional beverage industry, as reliable taste is the key to repeat consumption in a category that competes with all other enjoyable beverages. < Back The Hidden Science Behind Successful Cannabis Beverages Jan 5, 2026 James Stephens MG Magazine Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Cannabis beverage data is compelling. Analysts regularly point to alcohol substitution, faster onset formats, and expanding consumer acceptance. Capital is flowing in, large operators are launching drink lines, and every trade show seems to feature a new formulation promising better bioavailability and quicker effects. And yet, many of these products quietly underperform. Not because the science of delivery is wrong. Nanoemulsions work. Onset claims are often real. Stability can be achieved. The issue shows up somewhere else: the moment a consumer takes a sip and decides whether the taste is something they want to experience again. Why cannabis beverages underperform despite advanced delivery Anyone who has worked in conventional beverages recognizes this immediately. Liquids are unforgiving. There is no chew time, no fat matrix, no flavor delay. Aroma, bitterness, sweetness, and mouthfeel arrive all at once, and the product is judged instantly. This isn’t unique to cannabis; it’s a reality of beverage formulation. Cannabinoids bring familiar challenges to that format. They are bitter, oil-based, and sensitive to time and temperature. Those traits are not unusual. Caffeine, botanical extracts, vitamins, and countless nutraceutical ingredients behave the same way. The food-and-beverage industry has spent decades learning how to work with the challenges. Flavor is the real moment of truth [image: Close-up of carbonated bubbles in a laboratory beaker with a scientific pH probe, illustrating beverage flavor analysis.]Precision analysis of carbonation and pH balance is essential for ensuring a consistent consumer experience in every sip. (Image: mg Creative) What’s interesting is how often cannabis beverages borrow their technical playbook from pharmaceutical delivery rather than from beverage formulation. Pharmaceutical systems optimize for efficacy, with the goal of getting an active compound into the bloodstream quickly and efficiently. Beverage systems optimize for repeat consumption by making something people actually enjoy drinking. Cannabis beverages need both approaches, but many teams come from cultivation, extraction, or compliance backgrounds, not from flavor chemistry or beverage research and development. The result is a category full of drinks that deliver cannabinoids effectively but struggle to feel complete as beverages. This helps explain why certain flavor profiles appear again and again. Citrus-, berry-, ginger-, and cream-forward profiles are not trends so much as reliable tools. They carry aroma well, tolerate acidity, and integrate bitterness more gracefully than many alternatives. For example, citrus and ginger profiles are particularly effective at aiding terpene retention in beverages while masking off-notes. Used well, they allow the underlying formulation to disappear into the experience. Used poorly, they simply mask problems. Bitterness, sweetness, and mouthfeel aren’t optional Sweetness is a good example. Sugar historically did far more than make beverages taste sweet. It also added body, softened bitterness, and shaped how flavor unfolded on the palate. When sugar is reduced or removed for calorie content, positioning, or regulatory reasons, those functions must be replaced. If they aren’t, the drink feels thin, harsh, or unfinished, regardless of potency. Mouthfeel plays a similar role. Carbonation bite, viscosity, and finish influence how quality is perceived and how flavors register. A thin beverage amplifies bitterness; a well-structured one moderates it. Consumers rarely describe this explicitly, but their purchasing behavior reflects their perception. Preservation and stability shape consumer trust Preservation introduces another quiet failure point. Cannabis beverages often sit in a difficult middle ground: nutritionally rich enough to support microbial growth, not always acidic enough to self-preserve, and filled with compounds that oxidize over time. Without thoughtful preservation strategies that combine pH control, antioxidants, appropriate packaging, and sometimes mild preservatives, products lose potency, develop “off” flavors, or destabilize long before they reach consistent retail velocity. None of these challenges are novel. The flavor and beverage industries have addressed them for decades through techniques like bitterness modulation, encapsulation timing, textural engineering, and multi-hurdle preservation. The knowledge exists; it simply lives outside the cannabis echo chamber. Beverage science already solved these problems The cannabis beverages that perform best reflect beverage industry best practices, even if they do so unintentionally. Their taste is stable warm and cold. They finish cleanly. They don’t rely on extreme sweetness to get through the first sip. And, most importantly, people actually finish an entire serving. As the category matures, novelty will matter less than reliability. Cannabis drinks aren’t competing only with other cannabis products. They’re also competing with every other beverage consumers already enjoy. The brands that recognize that fact early tend to build quieter, more durable momentum. In beverages, chemistry gets a product to market. Flavor keeps it there. ------------------------------ Cannabis beverage flavor science: your questions, answered 1. Why do many cannabis beverages fail despite fast onset? Many fail because high-tech delivery doesn’t compensate for a poor drinking experience. Consumer retention depends on flavor, mouthfeel, and stability — not just potency. 2. What makes cannabis beverages harder to formulate than edibles? Liquids deliver aroma, taste, and texture instantly, leaving no buffer for bitterness or imbalance. Unlike edibles, beverages are judged immediately on flavor and mouthfeel. 3. Why is bitterness such a challenge in cannabis drinks? Because cannabinoids are naturally bitter, oil-based compounds. Success requires advanced bitterness masking and flavor modulation to ensure the consumer only tastes the intended profile. 4. How does mouthfeel affect cannabis beverage quality? Mouthfeel influences how bitterness is perceived and how “complete” a beverage feels. Thin drinks amplify harshness, while structured textures improve flavor integration. 5. What can cannabis brands learn from the beverage industry? The beverage industry has decades of experience managing bitterness, sweetness, stability, and shelf life — knowledge that cannabis brands can apply directly to improve repeat sales. 6. What are the biggest cannabis beverage consumer trends for 2026? The most significant trend is the “sober-curious” shift, where consumers swap alcohol for low-dose, fast-acting THC seltzers that offer a social buzz without the hangover. Additionally, there is a surge in demand for “functional” beverages that pair cannabinoids with adaptogens like ashwagandha or L-theanine for targeted wellness effects like stress relief and focus. ------------------------------ [image: James Stephens Sinful Brands] Flavor chemist and microbiologist James Stephens is co-founder of Sinful, a cannabis beverage platform focused on translating modern food and beverage science into repeatable, scalable THC experiences. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The Appellate Court of Maryland ruled that delta-8 and delta-10 THC are illegal in the state, despite lax enforcement. While Maryland has a regulated adult-use industry for delta-9 THC, the court determined that synthesized hemp products containing delta-8 and delta-10 THC are not covered by the legalization program. This decision came after the Maryland Hemp Coalition argued that the state’s cannabis regulations created an unconstitutional monopoly. Separately, Maryland collected $18.4 million in cannabis industry tax revenue from April to June 2025. < Back Maryland Court Rules Delta-8 and Delta-10 THC Products Are Illegal Sep 15, 2025 Graham Abbott Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link [image: Law books & justice symbol] The Appellate Court of Maryland ruled last week that delta-8 and delta-10 THC are illegal and have “always been illegal” in the state, although their “prohibition has been the subject of lax enforcement,” the Baltimore Sun reports. Maryland has a regulated adult-use industry offering legal access to delta-9 THC, which occurs naturally in large quantities in cannabis and in very small quantities in hemp — which, according to federal law, must contain less than 0.3% THC content. Delta-8 and delta-10 THC, meanwhile, are typically synthesized from other cannabinoids harvested from industrial hemp, which is federally legal. In June, the Maryland Hemp Coalition, a nonprofit hemp industry association, argued in a lawsuit filed under federal law that the state’s cannabis regulations constitute an unconstitutional monopoly that unfairly punishes unlicensed hemp businesses out of the market. But the court determined that because hemp products utilize cannabinoids that must be synthesized and don’t appear naturally in significant amounts, the intoxicants are not covered by the legalization program. “The ability to engage in the broader cannabis market generally and the limited hemp-derived psychoactive products market specifically is not a matter of common right … the Cannabis Reform Act is reasonably required for protecting public interest.” — Appellate Court Judge Dan Friedman, in the opinion, via the Sun Meanwhile, Maryland collected $18.4 million in cannabis industry tax revenue from April to June 2025, according to the latest quarterly report. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The Cannabis industry is on the cusp of a monumental shift with the potential rescheduling of Cannabis from Schedule I to Schedule III. This shift could unleash growth, investment, and opportunity, but it also means a new ballgame for accounting and tax. The benefits of rescheduling include increased participation from banks, access to capital markets, and interstate commerce. However, challenges will remain, including compliance and regulatory complexities. Accountants and financial professionals will play a critical role in this new landscape. Investors will expect solid financial controls, compliance with regulations, and clear growth strategies. The elimination of 280E could have a massive impact on valuations. The regulatory landscape will be complex, with continued state-level regulations and increased federal involvement. Accountants will need to stay updated with rapidly changing regulations. < Back Rescheduling Cannabis: How It Will Shake Up Accounting & Tax Jun 15, 2024 Dope CFO Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The Cannabis industry is on the cusp of a monumental shift that's about to rock the accounting and tax world. As a CPA with nearly a decade of experience in this niche, I've watched this industry explode from the ground up. We've gone from zero to a $33 billion legal market in 2023, with support for legalization at an all-time high. But hold onto your calculators, folks – what's coming next is going to make the past few years look like a warm-up lap. In April 2024, the DEA dropped a bombshell: they're considering rescheduling Cannabis from Schedule I to Schedule III. This isn't just another regulatory tweak; it's a seismic shift that could unleash a tidal wave of growth, investment, and opportunity. But it also means a whole new ballgame for accounting and tax in the Cannabis world. In this guide, we will provide an overview of how Cannabis rescheduling will impact accounting and tax, including: - The impact Cannabis rescheduling will have on valuations - How accounting and tax will change when Cannabis is rescheduled - What Cannabis accountants can do to prepare for Cannabis rescheduling - How Cannabis accountants can provide added value in the changing landscape If you're an accountant, investor, or Cannabis business owner, you need to be ready for what's coming. In this guide, I'm going to break down exactly how this rescheduling could shake up the industry, what it means for your bottom line, and how you can position yourself to ride this green wave to success. Let's dive in. *How Likely Is Cannabis Rescheduling?* One of the first questions we always get is, “how likely is Cannabis rescheduling or legalization?” People worry there is still a social stigma attached to marijuana and that it will impact not only the potential for rescheduling and legalization but also their potential for success in the Cannabis industry. According to an article published by Bloomberg, attitudes on Cannabis have shifted significantly in the last 50-60 years. Nearly 70% of all American adults now support full legalization. That is up from around 10% in 1969. (Source: Gallup) There is also bipartisan support for Cannabis legalization. Both red states and blue states support Cannabis legalization. For example, Cannabis is fully legal in Oklahoma, a traditionally red state, and Oregon, a historically blue state. (Source: mjbizdaily.com) You can poll any group you want - Republicans, Democrats, Independents - and you’ll find that a majority of adults support legalization. We have many examples of this across the United States. 24 out of 50 states now have full Cannabis legalization; we’ve seen that go from 0 to 24 in 10 years, and we expect that number to rise as we get closer to the 2024 election. All of that is to say, the industry and attitudes are changing. It will most likely begin with the DEA approving the rescheduling of Cannabis. Let’s look at what that means. *Understanding the Controlled Substances Act* The Controlled Substances Act established a federal drug policy that regulates the manufacture, importation, possession, use, and distribution of certain substances. The legislation created five schedules, or classifications, along with qualifications for a substance to be included in each. We’ll focus on Schedule 1, where Cannabis is currently scheduled, and Schedule III, the new proposed schedule for Cannabis. Schedule I is the highest and harshest schedule for a substance under the act. For a substance to be classified as Schedule I, it is said to have no medical use and high potential for both abuse and addiction. Other examples of substances classified as Schedule I include ecstasy, methamphetamine, heroin, and LSD. Something to note is that even drugs like fentanyl and oxycodone, which are responsible for tens of thousands of deaths annually, currently fall under Schedule II. Schedule III, the new proposed classification for Cannabis, is much milder. The substances in this classification have medical uses and while they still possess the potential for abuse and addiction, the risk is much lower. Other examples of substances in this classification include Tylenol, codeine, testosterone, and ketamine. Some of these are available over the counter while others are regularly prescribed by doctors. The DEA has recommended that Cannabis be moved from Schedule I to Schedule III. The reclassification would lead to a cascade of state and federal-level changes, and will completely change the market. *The Rescheduling Process* In October 2022, the Biden Administration launched an investigation into Cannabis being on Schedule I. The Health and Human Services (HHS) department recommended Cannabis be moved to Schedule III, and the FDA agreed. Now rescheduling is awaiting approval from the DEA. We’re cautiously optimistic as the DEA typically follows the recommendations from the HHS department. For now, things are looking green for the prospect of rescheduling at the very least. The Biden Administration is doing everything it can to gather votes and many industry experts, including us here at DOPE CFO, believe rescheduling will happen sooner rather than later. Let’s look at the benefits of rescheduling as well as some of the potential challenges that could arise. *Benefits and Challenges of Rescheduling* There are benefits and challenges that will come from rescheduling, We’ll start with the benefits. *Banking: from cash-only to full financial integration* The current banking situation for Cannabis businesses is, to put it mildly, challenging. Due to federal prohibition, most traditional banks have shied away from serving Cannabis clients, fearing potential legal repercussions. This has created a host of issues that have hampered the industry's growth and operational efficiency. Currently, many Cannabis businesses operate primarily in cash, which presents significant security risks and operational headaches. Imagine trying to manage payroll, pay taxes, or handle large transactions entirely in cash. It's not just inconvenient; it's dangerous and inefficient. Some Cannabis businesses have managed to secure limited banking services through state-chartered banks or credit unions willing to take on the risk and compliance burden. However, these services often come with hefty fees and restrictions, making them less than ideal for growing businesses. The lack of banking access has broader implications beyond day-to-day operations. Without bank accounts, Cannabis businesses struggle to build credit histories, making it nearly impossible to secure loans or lines of credit for expansion. This has forced many to rely on private investors or alternative funding sources, often at much higher interest rates than traditional business loans. Rescheduling Cannabis to Schedule III would fundamentally alter this landscape. While it wouldn't automatically solve all banking issues overnight, it would significantly reduce the perceived risk for financial institutions. Here's what we might expect: - *Increased Participation from Banks: *More banks, including larger national institutions, would likely begin offering services to Cannabis businesses. This increased competition could lead to better service offerings and reduced fees. - *Normalization of Financial Services:* Cannabis businesses could expect access to the full suite of financial services other industries take for granted. This includes business checking and savings accounts, merchant services for credit card processing, and payroll services. - *Electronic Payment Solutions:* With banking restrictions eased, we could see a proliferation of electronic payment solutions tailored for the Cannabis industry. This would reduce cash handling, improve security, and enhance the customer experience. - *Access to Capital Markets:* Improved banking relationships could pave the way for Cannabis businesses to access capital markets more easily. This could include everything from business loans and lines of credit to the ability to issue corporate bonds. - *Reduced Compliance Burden:* While compliance will always be a crucial aspect of Cannabis banking, rescheduling could simplify the reporting requirements for banks. This could make Cannabis accounts less costly to maintain, potentially reducing fees for businesses. - *Interstate Banking: *As the industry moves towards interstate commerce, having banking partners that can operate across state lines will become crucial. Rescheduling could make it easier for national banks to serve multi-state operators. However, it's important to note that challenges will remain. Banks will still need to comply with anti-money laundering laws and know-your-customer regulations. Cannabis businesses will need to maintain meticulous records and demonstrate full regulatory compliance to maintain their banking relationships. As accountants and financial professionals, our role in this new banking landscape will be critical. We'll need to help our clients navigate the transition from cash-based operations to full banking integration, ensuring they have the systems and controls in place to meet banks' requirements. Additionally, we'll play a key role in helping Cannabis businesses leverage their new banking relationships to fuel growth and improve operational efficiency. The shift in banking access represents a monumental change for the Cannabis industry. It's not just about having a place to deposit cash; it's about gaining access to the full spectrum of financial tools that can help these businesses scale, innovate, and compete in an increasingly sophisticated market. *Bankruptcy Protection: A Crucial Safety Net* Currently, Cannabis businesses operate in a precarious financial environment due to their inability to access bankruptcy protection. This is a direct result of Cannabis being classified as a Schedule I substance at the federal level. Let me illustrate why this is so significant. I've seen this impact firsthand. One of the first Cannabis farms I worked with went under, and the consequences were dire. Without the option of bankruptcy protection, there was no structured way to manage the business's decline. The result? A sudden closure that left many people jobless overnight. It's a scenario that plays out all too often in our industry, and it's one of the hidden risks that many don't consider when entering the Cannabis market. Rescheduling Cannabis to Schedule III could change this landscape dramatically. Here's what it might mean: 1. *Access to Chapter 11:* Cannabis businesses could gain the ability to file for Chapter 11 bankruptcy protection. This isn't about escaping debts; it's about providing a structured process for reorganization. It gives struggling businesses a chance to restructure their debts, renegotiate contracts, and potentially emerge as viable entities. 2. *Job Preservation:* With the option to reorganize rather than abruptly close, many jobs could be saved. In an industry that's becoming a significant employer in many states, this is crucial for local economies. 3. *Orderly Asset Distribution:* In cases where a business can't be saved, bankruptcy protection ensures a fair and orderly distribution of assets among creditors. This is far preferable to the current situation where the process can be chaotic and inequitable. 4. *Increased Investor Confidence:* The availability of bankruptcy protection could actually encourage more investment in the industry. Investors may be more willing to take risks if they know there's a structured process in place should things go wrong. 5. *Better Long-term Planning:* Cannabis businesses will be able to engage in more robust long-term planning, knowing they have this financial safety net if needed. It's important to note that while bankruptcy protection can be a lifeline, it's not a get-out-of-jail-free card. Businesses will still need to operate responsibly and maintain strong financial controls. As accountants and financial advisors, our role will be to help Cannabis businesses stay financially healthy and to guide them through the bankruptcy process if it becomes necessary. The introduction of bankruptcy protection to the Cannabis industry represents more than just a financial tool – it's a step towards normalizing Cannabis businesses in the eyes of the law and the financial sector. It's another piece of the puzzle in creating a stable, sustainable Cannabis industry that can weather economic ups and downs like any other sector. *Interested in Offering World-Class Accounting Services to the Cannabis Industry? * The Cannabis industry needs trained accountants now more than ever, to help them with compliance and maintaining a profitable, healthy business. We’ll teach you how to provide CFO-level support to growing companies in one of the fastest-growing industries in our generation. Click here to learn more. *Interstate Commerce: Breaking Down State Barriers* One of the most significant changes that rescheduling could bring to the Cannabis industry is the possibility of interstate commerce. This shift has the potential to completely reshape the market landscape. Let me break down what this could mean for the industry. *Current state of affairs * Right now, we essentially have 44 different state markets with varying pricing structures for similar products. It's a fragmented system that leads to inefficiencies and missed opportunities. For example, if you create an exceptional THC-infused kombucha in Oregon, you're limited to selling it within state lines. You can't ship it to Illinois, Oklahoma, or any other state, regardless of demand. This restriction limits growth potential and forces businesses to duplicate efforts across multiple states. *Opening new markets * Imagine a scenario where you could produce Cannabis products in one state and sell them across the entire country. This would allow businesses to: 1. Expand their customer base exponentially 2. Take advantage of economies of scale in production 3. Specialize in products that may have national appeal but limited local demand 4. Reduce costs by centralizing production in areas with optimal growing conditions or lower operating costs For instance, a California edibles manufacturer could suddenly access markets in Florida, New York, and everywhere in between. This opens up enormous growth potential for businesses that are currently constrained by state boundaries. *Challenges of state protectionism * However, it's not going to be a simple free-for-all. We need to be prepared for some pushback and complications: 1. *State-Level Protections:* States that have invested heavily in building up their local Cannabis industries may implement measures to protect these businesses from out-of-state competition. This could manifest as additional taxes on imported Cannabis products or licensing requirements for out-of-state businesses. 2. *Regulatory Disparities:* Different states have varying regulations on things like pesticide use, testing requirements, and product formulations. Navigating these differences for interstate sales will be complex. 3. *Tax Implications:* The current tax structures are based on intrastate commerce. Interstate sales will require new frameworks for how taxes are collected and distributed. 4. *Transportation Challenges:* Transporting Cannabis across state lines will require new security measures and tracking systems to prevent diversion to the black market. *Comparison to Other Industries * We might see a system develop similar to what we have with alcohol distribution. After Prohibition, many states implemented a three-tier system for alcohol sales, and we could see something similar emerge for Cannabis. This could involve separate licenses for producers, distributors, and retailers, with specific rules governing how products move between these tiers across state lines. *Implications for businesses and accountants * For Cannabis businesses, this shift will require: 1. Reevaluating business models and growth strategies 2. Investing in logistics and distribution networks 3. Navigating a more complex regulatory environment As accountants and financial advisors, we'll need to help our clients: 1. Understand the tax implications of selling across state lines 2. Develop systems for tracking multi-state sales and compliance 3. Evaluate opportunities for expansion or partnerships in new markets 4. Manage the increased complexity in financial reporting and auditing The move to interstate commerce represents both a massive opportunity and a significant challenge for the Cannabis industry. It has the potential to create national brands, drive down costs for consumers, and fuel rapid industry growth. However, it will also increase complexity and competition. Businesses that are prepared for this shift – with robust financial systems, clear strategies, and expert advice – will be best positioned to thrive in this new landscape. *Research and Development: Unleashing Innovation* Rescheduling Cannabis to Schedule III has the potential to dramatically accelerate research and development in the industry. This shift could unlock a new era of innovation, bringing together the worlds of Cannabis, pharmaceuticals, and biotechnology. Big pharma's entry into Cannabis One of the most significant changes we're likely to see is the entry of major pharmaceutical companies into the Cannabis space. These companies have been watching from the sidelines, hesitant to engage with a Schedule I substance. With rescheduling, we can expect them to dive in headfirst, bringing with them: 1. *Substantial R&D Budgets:* Pharmaceutical giants have deep pockets for research, potentially dwarfing current Cannabis R&D spending. 2. *Advanced Research Facilities:* Access to state-of-the-art labs and research tools could accelerate discoveries. 3. *Experienced Research Teams:* Scientists with expertise in drug development could bring new perspectives to Cannabis research. *Explosion of New Medicines and Products * This influx of resources and expertise could lead to a boom in new Cannabis-based medicines and products: 1. *Targeted Therapies:* We might see medications developed for specific conditions, moving beyond the current broad-spectrum approach of many Cannabis products. 2. *New Delivery Systems:* Research could yield innovative ways to administer cannabinoids, improving efficacy and patient experience. 3. *Isolating New Compounds:* Beyond THC and CBD, there are hundreds of cannabinoids and terpenes to explore. R&D could unlock the potential of these lesser-known compounds. 4. *Combination Therapies:* We might see Cannabis compounds combined with traditional pharmaceuticals for enhanced effects. Standardization and Quality Control Increased R&D is likely to lead to more standardized products: 1. *Consistent Dosing:* Pharmaceutical-grade products could offer more precise and reliable dosing. 2. *Quality Assurance:* Stricter manufacturing standards could improve product safety and consistency. 3. *Clinical Trials:* More robust clinical trials could provide stronger evidence for Cannabis's medical benefits. *Impact on the Industry * This R&D boom will have far-reaching effects: 1. Intellectual Property: We're likely to see a surge in Cannabis-related patents and proprietary formulations. 2. Job Creation: Increased R&D will create new jobs for scientists, researchers, and support staff. 3. Investment Opportunities: Companies with strong R&D pipelines could become attractive investment targets. *Challenges and Considerations * However, this shift also brings challenges: 1. Regulatory Navigation: Researchers will need to navigate FDA approval processes, which can be lengthy and costly. 2. Balancing Act: The industry will need to balance pharmaceutical development with the needs of existing medical Cannabis patients. 3. Small Players vs. Big Pharma: Smaller Cannabis companies might struggle to compete with the resources of large pharmaceutical corporations. *Implications for Cannabis Professionals * For those of us working in Cannabis finance and accounting, this R&D boom means: 1. New Valuation Metrics: We'll need to consider R&D pipelines and intellectual property in company valuations. 2. Complex Accounting: Tracking R&D expenses and capitalizing on successful developments will become crucial. 3. Funding Strategies: We'll need to help clients navigate funding options for costly R&D projects. 4. Tax Implications: Understanding R&D tax credits and how they apply to Cannabis businesses will be essential. The potential for R&D in a post-rescheduling Cannabis industry is enormous. It promises to transform not just the products available, but the entire landscape of the industry. As financial professionals, we need to be prepared to guide our clients through this new terrain, helping them capitalize on opportunities while navigating the complexities that come with increased research and development. *Regulatory Landscape: Navigating New Waters* Rescheduling Cannabis to Schedule III will significantly alter the regulatory landscape, but it won't simplify it entirely. In fact, we're likely to see a more complex, multi-layered regulatory environment emerge. Here's what we can expect: *Continued state-level regulation* Despite federal rescheduling, states will retain a significant role in Cannabis regulation: 1. Licensing: States will likely continue to control who can grow, process, and sell Cannabis within their borders. 2. Local Control: Many states allow municipalities to ban or restrict Cannabis businesses, a practice that's likely to continue. 3. State-Specific Rules: Expect continued variation in things like possession limits, home cultivation rights, and public consumption laws. This means Cannabis businesses will still need to navigate a patchwork of state regulations, especially if operating across multiple jurisdictions. *Federal oversight expansion * Rescheduling will bring increased federal involvement, primarily through agencies like the FDA and USDA: 1. FDA Oversight: The Food and Drug Administration will likely play a larger role in regulating Cannabis products, especially those making health claims. This could include: - Product safety standards - Labeling requirements - Marketing restrictions - Clinical trial oversight for medical claims 2. USDA Involvement: The U.S. Department of Agriculture may become more involved in setting standards for Cannabis cultivation, potentially including: - Organic certification processes - Pesticide use guidelines - Crop insurance programs 3. Federal Quality Standards: We might see the development of federal Good Manufacturing Practices (GMP) specific to Cannabis, similar to those in the pharmaceutical industry. Taxation Changes The regulatory shift will likely bring changes to the tax landscape: 1. 280E Reform: With Cannabis off Schedule I, we could see the end of 280E's application to Cannabis businesses, allowing for normal business deductions. 2. New Federal Taxes: However, don't be surprised if new federal excise taxes are introduced, similar to those on alcohol and tobacco. 3. State Tax Adjustments: States may need to adjust their tax structures in response to federal changes and to remain competitive with neighboring states. *Banking and financial services regulations * As banking opens up to the Cannabis industry, we'll see new regulatory frameworks emerge: 1. FinCEN Guidelines: Expect updated guidelines from the Financial Crimes Enforcement Network on how banks should work with Cannabis businesses. 2. Federal Reserve Policies: The Federal Reserve may need to create new policies for Cannabis banking, potentially including special reporting requirements. *Consumer Protection * With Cannabis becoming more mainstream, expect an increased focus on consumer protection: 1. Age Restrictions: Federal guidelines on age restrictions for Cannabis purchases may be implemented. 2. Product Testing: More rigorous and standardized testing requirements for potency, contaminants, and consistency. 3. Advertising Restrictions: Similar to tobacco, we might see federal restrictions on how Cannabis products can be advertised. *Environmental Regulations * The Cannabis industry's environmental impact will likely face increased scrutiny: 1. Energy Use: Regulations on energy consumption for indoor growing operations. 2. Water Usage: Guidelines on water use and runoff, especially in drought-prone areas. 3. Packaging Waste: Potential regulations on packaging materials and recycling requirements. *Implications for Cannabis Businesses and Financial Professionals * This evolving regulatory landscape will have significant implications: 1. Compliance Costs: Businesses will need to invest in robust compliance systems to navigate federal and state regulations. 2. Interstate Commerce Complexities: As discussed earlier, regulations around interstate Cannabis commerce will add new layers of complexity. 3. Increased Need for Expertise: Cannabis businesses will rely heavily on legal and financial professionals to navigate this new regulatory environment. 4. Reporting and Auditing: More complex regulations will require more sophisticated financial reporting and auditing processes. As accountants and financial advisors in the Cannabis space, we'll need to: - Stay up-to-date with rapidly changing regulations at both state and federal levels. - Help clients implement systems to ensure compliance across multiple regulatory frameworks. - Advise on the financial implications of new regulations, including tax changes and compliance costs. - Assist in preparing financial statements that meet new federal standards while still addressing state-specific requirements. The post-rescheduling regulatory landscape for Cannabis will be complex and dynamic. While it may resolve some current issues, it will undoubtedly create new challenges. Our role as financial professionals will be crucial in helping Cannabis businesses not just comply with these new regulations, but thrive within them. *Investors, Valuations, and Due Diligence: A New Era of Scrutiny* The rescheduling of Cannabis is set to dramatically alter the investment landscape. Let's dive into what this means for investors, company valuations, and the level of due diligence we can expect to see. *Investor landscape evolution * In the early days of the Cannabis industry, many investors got burned. They jumped in quickly, excited by the potential of this new market, without ensuring proper controls or good books were in place. The result? A lot of lost money and increased wariness among investors. Today's Cannabis investors are much more cautious and demanding. They're looking for businesses that can demonstrate: 1. Solid Financial Controls: Investors want to see that a company has robust systems in place to track and manage its finances accurately. 2. Compliance with Regulations: Given the complex regulatory environment, investors need assurance that businesses are operating within the law. 3. Strong Governance: Clear leadership structures and decision-making processes are crucial. 4. Growth Potential: Investors are looking for businesses that can scale and adapt in this rapidly changing industry. *Perpetual Data Rooms: A New Standard * One of the key demands we're seeing from investors is the implementation of perpetual data rooms. These are digital repositories that contain all crucial business documents and are continuously updated. They include: - Permanent files like leases, insurance policies, and tax returns - Regularly updated financial statements - Bank statements and invoices - What we call a "permanent audit trail" Having a well-maintained perpetual data room signals to investors that a business is organized, transparent, and ready for scrutiny. It's becoming a standard expectation, even for pre-revenue companies. *Valuations: The 280E effect * The potential elimination of 280E (the tax code that prohibits standard business deductions for Cannabis companies) could have a massive impact on valuations. Here's why: 1. Increased Cash Flow: Without 280E, Cannabis businesses could see their cash flow increase by 15-40%, depending on their effective tax rate and location. 2. Higher Net Income: The ability to deduct standard business expenses will significantly boost net income figures. 3. Multiplier Effect: These improvements in financial performance could lead to valuation increases of 5-10x almost overnight. For perspective, imagine a dispensary currently valued at $2 million. If 280E goes away, that same dispensary could potentially be worth $16 million. That's a game-changing increase for owners and investors. *Enhanced due diligence * With higher stakes and more institutional investors potentially entering the market, we can expect to see a much more rigorous due diligence process. This will likely include: 1. *Detailed Financial Audits:* Investors will want to see clean, accurate financial statements that can withstand scrutiny. 2. *Compliance Checks:* Thorough reviews of all licenses, permits, and adherence to state and local regulations. 3. *Operational Assessments:* Deep dives into business operations, supply chains, and growth strategies. 4. *Management Team Evaluation:* Close examination of the experience and track record of key personnel. 5. *Market Analysis:* Detailed assessment of the company's position in the market and growth potential. *Implications for Cannabis businesses * To attract investment and maximize valuations in this new landscape, Cannabis businesses need to: 1. *Implement Robust Financial Systems:* This includes detailed record-keeping, regular financial reporting, and strong internal controls. 2. *Maintain Impeccable Compliance:* Given the industry's regulatory complexities, businesses must be able to demonstrate strict adherence to all applicable laws. 3. *Develop Clear Growth Strategies:* Investors will be looking for well-thought-out plans for scaling and expanding the business. 4. *Build Strong Management Teams:* Having experienced, credible leadership will be crucial for attracting investment. 5. *Prepare for Scrutiny:* Businesses should be ready for a level of due diligence that may be more intense than they've experienced before. *The role of Cannabis Accounting Professionals * As accountants and financial advisors in the Cannabis industry, our role becomes even more critical in this evolving landscape. We need to: 1. Help clients build and maintain those all-important perpetual data rooms. 2. Ensure financial statements are audit-ready at all times. 3. Assist in developing financial models that can withstand investor scrutiny. 4. Guide clients through the complexities of valuation in a post-280E world. 5. Prepare clients for the level of due diligence they can expect from sophisticated investors. Our DOPE CFO Certified Advisors have helped clients raise over $10 million in cash. We know what investors and banks are looking for, and have access to several funding sources that are ready to provide capital. Give your clients the full suite of CFO services that they deserve by becoming a DOPE CFO Certified Advisor today. Click here to learn more. The rescheduling of Cannabis represents a massive opportunity for the industry, potentially unleashing a flood of new investment. However, it also means Cannabis businesses will be held to higher standards than ever before. Those that are prepared – with clean books, strong compliance, and clear growth strategies – will be best positioned to attract investment and achieve favorable valuations in this new era. *Descheduling vs Rescheduling * It’s also important to note that descheduling is different from rescheduling. Descheduling means you take it completely off the schedule. Ideally, that’s what we’ll see happen with Cannabis in the future. It's what happened with hemp and CBD back in 2018. If it comes off the schedules, then it could still be regulated by the state. For example, alcohol is not on schedules one to five and is regulated by the state, and can't be sold to minors. Different states have different laws. You know, in my home state of Oklahoma, you know, you couldn't drink craft brew during my years of growing up. Cannabis rescheduling will result in a lot of changes… But how will those changes affect accountants, bookkeepers, CPAs, and their clients? *How This Will Affect Accountants, Bookkeepers, CPAs, & Our Clients* The rescheduling of Cannabis will bring significant changes to the industry, and these changes will undoubtedly impact the work of accountants, bookkeepers, and CPAs serving Cannabis clients. The good news is that the fundamental principles of GAAP accounting will remain the same. This means that the core accounting practices you've honed will still be applicable, even as the industry undergoes transformation. *Accounting Changes* *280E and complex returns* The good news for us is - whether it's a farm, a processing plant, a manufacturer, a distributor, or a retailer - GAAP accounting is the same. It has nothing to do with the tax code and will remain complex and difficult to navigate. There will still be a need for cost accounting and the industry will still be multi-vertical. Just like every other complex niche in the US that is fully legal, like oil and gas or e-commerce or software, Cannabis will need niche experts to support their accounting. We’re likely to see lots of startups, cap raises, M&A, and exits as restrictions on the industry loosen. Things will heat up really quickly when rescheduling happens. Preparing taxes for Cannabis businesses is set to become more complex with rescheduling. Currently, due to IRC Section 280E, Cannabis businesses can't deduct most ordinary business expenses on their federal tax returns. However, they can include costs directly related to producing or acquiring their product as Cost of Goods Sold (COGS). Determining COGS for Cannabis businesses is already complicated. We must use GAAP cost accounting principles, specifically the rules under IRC Section 471, to calculate COGS accurately. This is crucial because COGS is considered a reduction of gross receipts rather than a deduction, allowing Cannabis businesses to recover some costs despite 280E restrictions. If Cannabis is rescheduled and 280E no longer applies, tax returns will likely become even more intricate. Businesses will need to navigate standard corporate tax rules, including various deductions and credits that were previously unavailable to them. This shift will require a more comprehensive approach to tax planning and preparation, potentially increasing the complexity of Cannabis tax returns. *Rescheduling and the Accountant’s Impact on Cannabis Company Valuations* To illustrate the potential impact of rescheduling on Cannabis company valuations, let's look at some data from leading multi-state operators (MSOs) in the industry. This information, compiled by the Green Market Report, provides a snapshot of current valuations and helps us project how these might change if 280E restrictions are lifted. (Source: Green Market Report) The chart shows various financial metrics for major Cannabis companies, including Enterprise Value (EV) to EBITDA ratios. These ratios are crucial for understanding how the market values these companies relative to their earnings before interest, taxes, depreciation, and amortization. Currently, we see EV/EBITDA ratios for 2023 estimates ranging widely, from as low as 4.57x for Ascend Wellness to as high as 53.10x for Glass House Brands. This wide range reflects the current uncertainty and variability in the Cannabis market. However, if 280E restrictions are removed, we could see a significant boost to these companies' EBITDA figures. Industry analysts, including those at Cannabis Business Executive, suggest we could see valuation multiples increase by a factor of 5 to 10 times current levels. To put this into perspective, let's consider a hypothetical example. If a Cannabis dispensary is currently valued at $2 million, the elimination of 280E could potentially increase its value to $16 million - an 8x increase. This dramatic rise would be driven by the sudden ability to deduct ordinary business expenses, significantly improving profitability and cash flow. This potential for value creation is not just theoretical. It represents real opportunities for business owners, investors, and even employees in the Cannabis industry. It also underscores the critical importance of proper financial management and reporting in the sector. As accountants and financial advisors, our role in helping Cannabis businesses navigate this potential transition and maximize their valuations will be more crucial than ever. *Is it going to be Challenging for Cannabis CFOs?* The road ahead for Cannabis CFOs is undoubtedly challenging. Regardless of whether Cannabis is descheduled or rescheduled, the industry will remain highly complex. CFOs will need to navigate extensive compliance requirements, limitations in vendor services, and the integration of numerous Cannabis-specific software solutions. The industry's rapid growth and evolving regulatory landscape will further compound these challenges. However, these challenges also represent an exciting opportunity for growth and innovation. As the industry matures, we can expect to see the development of more sophisticated accounting tools and industry-specific guidance. The increasing demand for skilled professionals in Cannabis accounting and finance underscores the potential for a rewarding and impactful career in this field. Despite the complexities, the Cannabis industry presents a promising future. Even without federal rescheduling, the industry has experienced massive growth, with states like Ohio and Minnesota recently legalizing Cannabis. The potential for full legalization in Florida and continued growth in states like Michigan and Massachusetts further highlights the industry's upward trajectory. This growth translates into a wealth of opportunities for accountants, CFOs, and CPAs willing to embrace the challenges and complexities of this booming and exciting industry. Our nationally recognized Cannabis accounting program has seen a surge in students eager to tap into these opportunities, even in states where Cannabis remains illegal. This demonstrates the growing recognition of the potential for success in Cannabis accounting and finance, regardless of location. The evolving Cannabis landscape is ripe with possibilities, and those prepared to navigate its complexities will be well-positioned to thrive. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Michigan’s leading cannabis trade group has filed a lawsuit to challenge the new 24% wholesale tax recently signed into law by Gov. Gretchen Whitmer. The news was posted by MJBizDaily, a source for financial, legal, and cannabusiness news. < Back Legal battle brews over Michigan’s new marijuana tax Oct 8, 2025 Margaret Jackson MJbizDaily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Michigan’s leading cannabis trade group filed a lawsuit challenging the new 24% wholesale tax Gov. Gretchen Whitmer recently signed into law. Legal battle brews over Michigan’s new marijuana tax is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The endocannabinoid system (ECS) is vital for mammalian health, regulating basic functions like sleep, appetite, mood, and immune response. A balanced ECS is crucial, as imbalance can lead to various health issues. While cannabis can optimize the ECS, five alternative ways to boost it include reducing alcohol intake, getting bodywork treatments (like massage and acupuncture), eating leafy greens (which contain beta-caryophyllene), consuming omega-3 fatty acids, and engaging in enjoyable exercise. < Back 5 Simple Ways to Boost Your Endocannabinoid System Without Cannabis Oct 15, 2025 Dragonfly de la Luz Cannabis Now Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Our bodies all have a network of cannabinoid receptors that is vital to the health of all mammals: the endocannabinoid system. The ECS is a vast network of chemical compounds and receptors (namely CB1 and CB2) that regulate our most basic functions – sleep, appetite, mood, the immune system, inflammatory response, aging and memory. Endocannabinoids even produce feelings of relaxation and euphoria similar to those which come from ingesting cannabis. Aside from regulating essential everyday functions, the ECS maintains the body’s homeostasis down to the cell level by reversing damage in whatever way necessary. In cancer patients, for instance, cancer cells can be programmed to kill themselves when endocannabinoid levels increase. [image: boosting endocannabinoid system with omega 3s leafy greens no alcohol exercize] But as with most things, balance within this system is key. An overly inhibited CB1 receptor may lead to moodiness, depression and a suppressed immune system. On the other hand, an over-activated CB1 can increase risk of psychoactivity, inflammation, diabetes, obesity and cardiovascular problems. One study found that a highly sensitive endocannabinoid system is linked to almost all chronic diseases. So, a balanced ECS is fundamental to good health. Consuming cannabis is one fun and easy way to optimize the ECS. But not everyone has the freedom to enjoy this medicinal plant. Here are our top five simple ways to boost the endocannabinoid system without the aid of marijuana. * Drink Less Alcohol* Martin Lee, director of Project CBD and author of “Smoke Signals: A Social History of Marijuana – Medical, Recreational and Scientific,” explained the problem with drinking: “Alcohol is a poison that causes an acute stress response upon occasional consumption, which, in turn, provokes a temporary uptick of endocannabinoid activity as a protective response against stress,” Lee said. He added that while occasional drinking probably wouldn’t harm the ECS, “chronic alcoholism has the opposite effect, resulting in a depletion of endocannabinoid tone due to the wear and tear of too much stress. A low endocannabinoid baseline level makes a person more vulnerable to disease.” * Get Bodywork Treatments* A study by Auckland’s Unitec Institute of Technology showed that levels of anandamide — a cannabinoid responsible for feelings of bliss and joy — more than doubled after patients received osteopathic manipulative medicine treatments. This therapy can take various forms, including chiropractic, physical therapy and massage. Even acupuncture has a positive effect on the endocannabinoid system, so there’s never been a better excuse to take a spa day. * Eat Leafy Greens* If smoking frosty greens is not an option, then eating leafy greens will suffice. Along with oregano and black pepper, leafy greens contain beta-caryophyllene, a terpene that activates the CB2 receptor and is believed to have high potential for combatting inflammatory conditions and autoimmune disorders. * Eat More Omega-3s* Omega-3 fatty acids are essential for a well functioning ECS. Some scientists say that without them, CB1 receptors may not form correctly, which could lead to “impaired emotional behavior.” While fish oils are widely considered one of the best sources of omega-3s, hemp is an excellent alternative. Whether in seed, oil or protein form, hemp’s omega-3s can help keep your ECS functioning properly. * Exercise * German researchers have shown that “runner’s high” is not actually caused by an endorphin rush, but instead is a result of an increase in endocannabinoid production. And running isn’t the only activity that produces this effect. Any exercise can lead to an increase in endocannabinoids, so long as the activity doesn’t feel forced. The body interprets forced exercise as a stressor, which can actually produce the opposite effect and decrease endocannabinoid receptor signaling. So, dust off the yoga mat, jump up and down on a trampoline or even go out dancing to maintain a healthy endocannabinoid system. *Originally published in the print edition of Cannabis Now.* *LEARN MORE* *TELL US, *how do you combine cannabis with other wellness techniques? The post 5 Simple Ways to Boost Your Endocannabinoid System Without Cannabis appeared first on Cannabis Now. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

YANA Wellness, a women-owned and operated cannabis brand led by CEO Ariana Fleishman, made history as the first hemp-derived THC beverage line sold in all Total Wine retail locations across Virginia. Fleishman established the brand to advocate for plant-based wellness alternatives over normalized alcohol and prescription drugs, developing a variety of compliant blends to navigate federal prohibition and expand nationwide access. YANA emphasizes social responsibility, research (collaborating with universities on the psychological effects of cannabis and mushrooms), and stimulating the local economy through strategic partnerships with family-owned Virginia businesses for manufacturing and distribution. < Back YANA Wellness Becomes First Women-Owned and Operated THC Drink Line in All Virginia Total Wine Locations Dec 15, 2025 Cannabis Now Cannabis Now Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link YANA Wellness, a women-owned and operated cannabis brand with a licensed dispensary in Washington, DC, officially makes history as the first hemp-derived THC beverage line in all Total Wine retail locations across Virginia. Their e-commerce platform also reaches consumers with their plant-based alternative drinks nationwide. This marks a major milestone not only for YANA as a small, women-owned business, but for all women pioneering plant-based wellness products for nationwide distribution. The Founder and CEO of YANA, Ariana Fleishman, has made a blueprint for minority small business owners to create accessible, compliant and community-driven products. Fleishman utilizes her social media platforms to educate consumers and business owners alike. “YANA stands for You Are Not Alone, and it is also the nickname my mom gave me as a kid. I’ve always wanted to create a community around this mission. Mental health issues are at an all-time with everything going on in the world today. I truly believe you can’t change the world until you change your own community,” Fleishman says. “Adderall and alcohol—these are so normalized in today’s society. My doctor would prescribe me Adderall for the workday to combat my ADHD. Then at night, bars and restaurants only have alcohol on the menu, which completely impairs my memory and makes me feel so sick the next day. Why is this lifestyle still so normalized? Why do we have to be so quiet when we choose to consume plants over poison?” “Cannabis and Mushrooms are already clinically proven to be an effective medicine and provide so many life-changing benefits when purchased from lab-tested and credible sources,” she continues. “But still, the norm is to take highly addictive drugs prescribed by doctors and to drink alcohol to socialize with friends. My goal is to change this stigma by providing plant-based alternatives in mainstream settings.” *Breaking Down Prohibition Barriers and Entering the Mainstream Market* With cannabis still under federal prohibition, Fleishman purposely developed a variety of plant-based alternative blends so that at least one of their drinks on the product line would meet all jurisdictional regulations in every state. This was her strategy for expanding the brand and the plant-based alternatives culture into new markets while cannabis legalization is still uncertain nationwide. Consumers can now find YANA drinks on restaurant menus in the DMV area and can explore the benefits of cannabinoids, functional mushrooms and adaptogens without fear of the negative stigma. YANA’s Rizzi Mushroom Elixir is a consumer favorite that contains no THC or CBD—just a federally legal blend of nootropic and adaptogenic mushrooms. Rizzi Elixir is featured at premiere social clubs in DC, like Ciel Rooftop at Marriott’s Downtown Hotel and Spark Social, DC’s first non-alcoholic social club for the LGBTQ+ community. These mainstream venues showcase how plant-based alternative drinks can be part of a holistic social wellness lifestyle—and it’s only the beginning. Virginia can now legally sell hemp-derived THC drinks in bars and restaurants with a hemp license as well. Learn more about their full product line and check out where you can buy YANA drinks near you here. *Women Leading the Future of Cannabis* YANA’s success story symbolizes the perseverance of women who have navigated the cannabis industry’s challenging transition from prohibition to legitimacy. Fleishman and her team have emerged from the “gray market” era in DC after five years in the industry to now operating a fully legal, women-run cannabis dispensary. The Chief Strategy Officer of YANA Wellness Brands, Hannah Clarke, a longtime cannabis lobbyist and consultant, emphasizes the significance of their achievements: “Women are not just participating in the industry anymore—we’re building it,” Clarke says. “This is about changing perceptions, policy and the path forward for future generations of women in cannabis.” YANA prioritizes education, research and inclusion, integrating science, advocacy and entrepreneurship opportunities for their team of young women entering the workforce. Through wellness program collaborations with clinical psychologist Dr.Vivid and university internship programs with American University and the University of Maryland, YANA Wellness offers students the rare opportunity to study the psychological effects of cannabis and mushrooms to properly sell and promote these alternative medicines to conscious consumers. “I’ve been interested in psychology for a while, but I never imagined I’d find an internship that focuses on the psychological effects of cannabis and mushrooms, at least not so early in my career,” said Lucrezia Brody, a YANA psychology intern and student at American University. “The research we conduct isn’t just filed away—it directly informs our patients and wellness consultants to help improve our community.” *Expanding While Stimulating the Local Economy* YANA is operated by a small team of 10 women, but their strategic partnerships with local, family-owned businesses in Virginia are how YANA is scaling effectively and stimulating the local economy. Fleishman knows that the cannabis market is already dominated by MSOs (multi-state operators) in healthcare, largely owned by publicly traded companies and pharmaceutical businesses, so she has devoted herself to working with local small businesses in all parts of the supply chain. Pure Shenandoah is a family-owned hemp manufacturing business that provides high-quality cannabis extractions, and Brothers Craft Brewery is a family-owned brewery that YANA uses for canning their drinks. “It was very important to me to stimulate the local economy that I grew up in and keep my mission of building community through plant medicine alternatives,” Fleishman states. YANA also just signed with Specialty Beverage, a family-owned beverage distribution company known for its large-scale deliveries to mainstream businesses. This partnership increases the accessibility of hemp-derived THC beverages to reach retail locations and restaurant menus that want to provide plant-based alternatives to alcohol. *The Evolution of YANA* In 2019, Ariana Fleishman, also known as “Ari Tokes” on social media, founded YANA Wellness as Cannabis Creatives Collectives for the DC metropolitan area to connect with others through curated social experiences. As the laws changed in DC, YANA evolved into a Holistic Wellness Center and Licensed Cannabis Dispensary. Fleishman simultaneously spent two years developing the YANA drink line while opening the retail location so she could reach people nationwide with a variety of plant-based alternative blends. Through their social media platforms, YANA continues to advocate for responsible, inclusive and research-backed cannabis culture nationwide. Stay tuned in on their social media for updates on community events, cannabis news, and the culture here. The post YANA Wellness Becomes First Women-Owned and Operated THC Drink Line in All Virginia Total Wine Locations appeared first on Cannabis Now. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The California State Fair honored the top cannabis cultivators and manufacturers, with over 600 entries competing for awards. < Back Golden Bear Awards: California’s 2025 Best Cannabis Flower, Products Announced Jul 16, 2025 staff Cannabis Business Times Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The California State Fair recognized the state’s best cannabis cultivators and manufacturers, with more than 600 entries for the top prizes. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The author, Ryan Basore, a former federal prisoner for medical cannabis cultivation, launched Redemption Cannabis and the Redemption Foundation. His cannabis brand is now available in West Virginia, where he was incarcerated. The Redemption Foundation provides expungements and financial support to non-violent cannabis offenders still in prison, partnering with organizations like Mission Green and the Last Prisoner Project. Basore emphasizes that despite widespread legalization, many people remain incarcerated for cannabis offenses, and federal law, which classifies cannabis as a Schedule I drug, needs to change for true justice. He states that 10% of Redemption Cannabis licensing revenue supports incarcerated individuals and their release, highlighting that buying their products contributes to the pursuit of justice. < Back Today My Cannabis Brand Launches In West Virginia, Where I Spent Years Behind Bars For Growing Medical Marijuana (Op-Ed) Jul 11, 2025 Marijuana Moment Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link *“Legalization is progress, but we won’t be satisfied until every cannabis prisoner is set free.”* *By Ryan Basore, Redemption Cannabis and The Redemption Foundation* A little over a decade ago, I was sitting in a federal prison in Morgantown, West Virginia, serving time for growing medical cannabis in compliance with Michigan’s state law. I wasn’t a trafficker. I wasn’t running guns or laundering money. I was a state-licensed caregiver using cannabis to help people with debilitating conditions. Then I became one of the thousands targeted during a time when the federal government treated medical cannabis providers like public enemies. Today—July 11—my cannabis brand launches in the same town in which I spent years behind bars for growing medical cannabis. As traumatic as that experience was, I knew I couldn’t let it deter me from doing what’s right. That’s what led me to found Redemption Cannabis, one of Michigan’s top-selling cannabis brands and one that supports those still serving time for nonviolent cannabis offenses. Together with partners like Trulieve and Altvm, we provide cannabis products to patients and consumers across states like Michigan, Maryland, Oklahoma, Pennsylvania and now West Virginia, where I once wore prison tans. It’s a redemption story I’m proud of, but it’s also a privilege that too many others have been denied. Despite widespread legalization across a majority of U.S. states, many in the U.S. remain incarcerated for cannabis offenses. Their “crime”? Often the same actions that built today’s billion-dollar cannabis industry. Legalization has crept forward, but justice has not. I launched the Redemption Foundation in 2019 to change that. Through our programs, we’ve helped fund over 2,000 free expungements and provided direct financial support to federal cannabis prisoners across the country. One of our core efforts is our commissary program, which puts up to $300 a month, the maximum allowed, on the books of people incarcerated for non-violent cannabis offenses. For someone earning $14 a month in prison wages, that support isn’t just helpful. It’s life-changing. We also partner with organizations like the Weldon Project’s Mission Green and the Last Prisoner Project to expand our reach and impact. The goal isn’t just release, it’s restoration. That means helping people return to their communities, access housing, find jobs and reclaim their dignity. But here’s the hard truth: Unless federal law changes, we will keep seeing these contradictions. The Controlled Substances Act still classifies cannabis as a Schedule I drug, a substance with high risk for abuse with no currently accepted medical use. Until that changes, people will keep getting sentenced, even as legalization spreads. Even expungement isn’t enough. In many states, it isn’t automatic. People need attorneys, paperwork, court appearances and other resources that are rarely made accessible to them just to be able to live a normal life. They struggle to find work, obtain housing or move on with their lives. Meanwhile, a lucrative industry has emerged around cannabis, the foundations of which were put in place by pioneers who continue to suffer behind bars or remain locked out of the legal industry. Those of us who now enjoy the ability to consume and profit from legal cannabis owe our freedom to the people who took risks when it wasn’t safe or legal to do so. We have to recognize that our prosperity is a result of their sacrifice. That’s why 10 percent of all Redemption Cannabis licensing revenue goes to supporting those still incarcerated and to securing their release. When you buy our products, you’re not just consuming, you’re contributing to the pursuit of justice. Redemption isn’t just our brand name. It’s our mission. Legalization is progress, but we won’t be satisfied until every cannabis prisoner is set free. *Ryan Basore is the founder of Redemption Cannabis and the Redemption Foundation, which supports cannabis prisoners and fights for restorative justice in the cannabis industry. He previously served a federal sentence for medical marijuana cultivation in Michigan.* *Photo courtesy of Chris Wallis // Side Pocket Images.* The post Today My Cannabis Brand Launches In West Virginia, Where I Spent Years Behind Bars For Growing Medical Marijuana (Op-Ed) appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Tilray Brands is a leading global cannabis-lifestyle and consumer packaged goods company, diversifying its portfolio across cannabis, wellness, beverages, and lifestyle products worldwide, and emphasizing quality and compliance across its operations. < Back Tilray Brands Jan 9, 2026 Darren Roberts MG Magazine Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Tilray Brands *Tilray Brands, Inc.* is a leading global cannabis‑lifestyle and consumer packaged goods company at the intersection of cannabis, wellness, beverages, and lifestyle products. The company operates a diversified portfolio of brands across multiple markets worldwide and is committed to expanding access to high‑quality cannabis and beverage offerings. ( ir.tilray.com) [image: Tilray Brands Logo] Your browser does not support the video tag. Partner Content Founded in 2013, Tilray Brands has grown into one of the most diversified global lifestyle companies linking cannabis, beverages, wellness products, and consumer packaged goods. The company operates across North America, Europe, Australia, and Latin America, with a mission to elevate lives through innovative products and moments of connection. Tilray’s core business includes the research, cultivation, manufacturing, and distribution of medical and adult‑use cannabis products. Its expansive portfolio serves patients, recreational users, and retail partners worldwide — from premium flower and extracts to hemp‑derived wellness goods. Beyond cannabis, Tilray has strategically expanded into the beverage and craft beer sectors through the acquisition of well‑known breweries and beverage brands. These operations complement its wellness foods and non‑alcoholic beverage offerings, making Tilray a truly comprehensive lifestyle company. Tilray also emphasizes quality and compliance, with Good Manufacturing Practices (GMP) certifications and global partnerships that support innovation and access to high‑standard medical cannabis products. ( tilraymedical.eu.com) Company Details *Industry:* Cannabis & Consumer Goods *Founded:* 2013 *Headquarters:* New York City, United States *Status:* Public *Stock Symbol:* NASDAQ: TLRY *Operations:* Canada, U.S., Europe, Australia, Latin America *Website:* tilray.com Connect with Tilray [image: X (Twitter)] [image: Instagram] [image: Facebook] [image: LinkedIn] Affiliated Products [image: Fizzy Jane's Logo] < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Pennsylvania senators have introduced a bipartisan bill to create a new regulatory body, the Cannabis Control Board (CCB), to oversee medical cannabis and prepare for eventual adult-use legalization. The bill, sponsored by Senator Dan Laughlin, aims to establish a transparent and efficient framework for the cannabis industry, ensuring the state is ready when adult-use legalization passes. The CCB would consolidate oversight, enhance transparency, and manage the industry. While the bill doesn't explicitly legalize adult-use cannabis, it sets up the infrastructure for it. Democrats and some Republicans support legalization due to public health and safety concerns, economic benefits, and competitiveness with neighboring states that have already legalized. Despite bipartisan voter support, the reform faces hurdles in the legislature due to conflicting views on a state-controlled versus private sales model and the need for Republican support in the GOP-controlled Senate. < Back New Bipartisan Pennsylvania Bill Would Create Marijuana Regulatory Board Ahead Of Possible Adult-Use Legalization Jul 1, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Bipartisan Pennsylvania senators have introduced a bill to create a new regulatory body in the state that would begin overseeing medical cannabis while preparing to eventually handle the adult-use market as well. The 52-page legislation is being sponsored by Sen. Dan Laughlin (R), along with 16 other members from both parties. While it wouldn’t legalize adult-use cannabis as the lead sponsor has supported, it would establish a regulatory infrastructure that could be used to oversee such a program. Laughlin, who has sponsored legalization bills in the past, previewed the new measure in May, writing that Pennsylvania should first take steps to make sure the state is “ready to act when legalization becomes law” by establishing a Cannabis Control Board (CCB) now. “Legalization of adult-use cannabis in Pennsylvania is no longer a matter of if, it is when. And when that day comes, the state should not be scrambling to build a regulatory system from scratch,” he said. “A transparent, efficient framework should already be in place, one designed to support a safe, well-regulated cannabis industry from day one.” At the time, he indicated that the board would also be responsible for regulating the hemp market under the proposal, but the language of the introduced legislation is somewhat opaque on that component of the cannabis industry. In a cosponsorship memo, the senator said his bill would “transfer regulatory control of the Medical Marijuana Program to the CCB, ensuring continuity, efficiency, and improved oversight of medical cannabis businesses and patient access.” It would further “establish uniform safety standards to protect consumers from untested and potentially harmful products.” The bill text itself also doesn’t contain an explicit references to adult-use, or recreational, marijuana, and it would not enact legalization on its own. But the description indicates that the sponsors feel the current regulatory regime under the Pennsylvania Department of Health should be replaced with a more targeted agency that would ostensibly be suited to oversee an adult-use market if lawmakers move to end prohibition. “By consolidating oversight under a single regulatory board, we can eliminate inconsistencies, enhance transparency, and provide the structure needed to responsibly manage this industry,” the memo says. Most of the bill describes the process of establishing the CCB, with details about the selection criteria and other procedural information. The duties section of the legislation lists various authorizations for the board, including members’ ability to conduct investigations, promulgate regulations, consult with other departments and more to achieve its oversight goals. Meanwhile, Sen. Shariff Street (D), one of the original cosponsors of the new bill, said last week that he was working with bipartisan and bicameral lawmakers to develop a passable marijuana legalization measure as the legislature approached Monday’s budget deadline—telling supporters at the time that “we’re getting close” and they shouldn’t “ease up” on the fight. “There are some basic things that we know we need to have done,” he said. “We need to make sure when we pass a recreational adult-use bill that we seal and expunge the records of all those people who’ve been who’ve had cannabis convictions in the past.” Street thanked his bipartisan colleagues in the House—including Reps. Emily Kinkead (D), Abby Major (R) and Amen Brown (D), who have championed their own legalization proposals—for working with the Senate “in a collaborative way.” “We have a good core group of us who’ve been working to move this bill—to move this concept forward—and I think we’re gonna get it done,” he said. “We need your voices to stay engaged. We need to stay involved.” Meanwhile, Senate Majority Leader Joe Pittman (R) recently said marijuana legalization would not be included in the 2026 budget as lawmakers approached the deadline he expected they would miss. But Gov. Josh Shapiro (D) is still holding out hope that negotiators can “get it done.” Legislators appear to be at an impasse on certain key issues, including the governor’s request to legalize adult-use cannabis via the legislation. Pittman said he doesn’t see a path forward for the reform on that schedule, however. Shapiro, on the other hand, hasn’t quite thrown in the towel, saying at a press briefing earlier last month that “we all understand we have to compromise” on a number of issues to reach a budget agreement. Pittman, for his part, criticized House lawmakers for passing a marijuana legalization bill that would have involved state-run shops. The legislation was quickly rejected by a Senate committee. Following that defeat, the governor said he still remained “hopeful” that lawmakers could deliver a reform bill to his desk by a budget deadline at the end of last month—and he urged the GOP-controlled Senate to “put their ideas on the table.” “We’ve had really good, honest dialogue about it,” the governor, who separately criticized the Senate for abruptly derailing the House marijuana legalization bill, said. “Look, I think this is an issue of competitiveness,” he said. “Every state around us, with the exception of West Virginia, has gotten it done. You go visit some of these dispensaries along our border—in this case with Maryland, [that] is probably the closest one here. Sixty percent of the people walking into those dispensaries are from the Commonwealth of Pennsylvania.” Whether Pennsylvania legislators will advance legalization this session remains to be seen. But two Democratic lawmakers—Street and Rep. Rick Krajewski (D)—recently said they’re aiming to reach a compromise and pass reform legislation before the budget deadline. Also, in May, Sen. Marty Flynn (D) announced his intent to file a new bill to legalize marijuana in the state, calling on colleagues to join him on the measure. While the House legislation Krajewski sponsored alongside Rep. Dan Frankel (D) was rejected in a Senate committee following its expedited passage through the House along party lines, Street said he’s “cautiously optimistic we’re going to be able to revive the bill and amend it and move forward with a work product that allows us to get a bill on the governor’s desk and realize revenue.” Following the Senate committee vote, lawmakers from both chambers who support legalization have been trading criticisms about each other’s roles in the stalled push to end prohibition. Krajewski, for example, recently wrote in a Marijuana Moment op-ed that Senate Republicans who killed his House-passed cannabis legalization bill are “stuck in their prohibitionist views of the past” and are “out of touch with the will of our Commonwealth.” Prior to that vote, Pennsylvania’s Republican attorney general said that while he doesn’t currently support the House-passed marijuana legalization bill, he’s open to changing his mind about the policy change after continuing to review the details. For what it’s worth, a recent poll found that Pennsylvania voters say they favor a model where cannabis is sold by licensed private businesses, rather than through a system of state-run stores. The governor has repeatedly called for adult-use marijuana legalization. However, he hasn’t endorsed the specific idea of having a state-controlled model. GOP lawmaker Major—who is sponsoring another forthcoming legalization bill that envisions a traditional private sales model alongside Democrat Kinkead—said during the House floor debate on HB 1200 that she stands opposed to the competing bill, emphasizing that she disagrees with the state-run stores proposal. While Democrats control the House and governor’s office, they will still need to reach a deal with the GOP-controlled Senate to effectuate change. And in addition to the conflicting perspectives among pro-legalization legislators, another potential barrier to reform is exactly that political dynamic. Regardless of which direction Pennsylvania lawmakers do—or don’t—go on marijuana legalization this session, a survey released in April shows a majority of adults in the state support the reform—and opposition to the policy change has fallen by nearly 50 percent over the last decade. Kinkead has made the case in another recent interview that legalizing cannabis in Pennsylvania will help the state mitigate public health and safety concerns associated with the illicit market, including the fact that unregulated products can be laced with fentanyl. The lawmaker previously introduced a separate bipartisan marijuana legalization bill, alongside 15 other cosponsors, last September. It did not advance, however. Meanwhile, Laughlin recently called for the creation of a state “legacy” fund, using tax revenue from adult-use marijuana sales and gaming to make long-term investments in the Commonwealth’s economy. The senator argued that, beyond using any resulting tax revenue to fund day-to-day projects and public services, the state should earmark a portion of those tax dollars for a fund to “provide a sustainable source of prosperity that lasts for generations.” Another GOP Pennsylvania senator, Sen. Gene Yaw (R), is backing the push to legalize marijuana in the commonwealth, pointing out that, historically, prohibition “has not turned out well,” noting the country’s experience with alcohol criminalization. Pennsylvania House Speaker Joanna McClinton (D) recently said that Democrats are ready to pass a marijuana legalization bill this session, but that the party “will need Republican support” to get the job done—adding that it will be a “heavy lift.” Polls have shown bipartisan support for legalization among voters, but the reform has consistently stalled in the legislature, owing in large part to GOP opposition. But not all Republican members are against the policy change—and one recently said she felt her party should seize the “opportunity to snatch” the issue from Democrats. Separately in March, the Pennsylvania House approved a bill sponsored by Frankel that’s meant to strengthen safety standards and oversight of the state’s medical marijuana program as lawmakers work to advance adult-use legalization. While Pennsylvania’s medical cannabis program was enacted nearly a decade ago, lawmakers say the measure, which now heads to the Senate, is necessary to improve testing compliance, product audits and lab inspections, among other aspects of the industry. Meanwhile, Pennsylvania Democratic lawmakers recently introduced a bill that would allow farmers and other small agriculture operators to sell marijuana they cultivate to existing growers and and processors if the state moves to legalize adult-use cannabis. Separately, an independent Pennsylvania agency is projecting more tax dollars to be generated from adult-use marijuana sales compared to what the governor’s office has estimated, although it expects significantly less overall revenue from cannabis legalization due to differing views on licensing fees. Pennsylvania officials have also launched a new survey that invites legal marijuana businesses across the country to provide information about their operations to help the state better understand the cannabis industry as lawmakers consider enacting adult-use legalization this session. *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* Also, in a video interview released in March, the governor emphasized that the state is “losing out” to others that have already enacted adult-use legalization, while maintaining a policy that’s enriched the illicit market. “I think it’s an issue of freedom and liberty. I mean, if folks want to smoke, they should be able to do so in a safe and legal way,” he said. “We should shut down the black market—and, by the way, every state around us is doing it. Pennsylvanians are driving to those other states and paying taxes in those other states.” The state’s agriculture secretary separately told lawmakers that he’s fully confident that his department is in a “really good” position to oversee an adult-use marijuana program if lawmakers act. Meanwhile, in February, top Pennsylvania police and health officials told lawmakers they are prepared to implement marijuana legalization if the legislature moves forward with the reform—and that they stand ready to work together as the details of legislation to achieve it are crafted. Amid the growing calls for marijuana legalization in Pennsylvania, a GOP state senator said prohibition has been a “disaster,” and a regulated sales model for cannabis—similar to how alcohol and tobacco are handled—could serve as an effective alternative. A Republican Pennsylvania senator also recently defended the push to legalize and regulate marijuana, calling it “the most conservative stance” on the issue. New Hampshire Bill To Ease Psilocybin Penalties Advances Through House But Is Tabled In Senate *Photo courtesy of Mike Latimer.* The post New Bipartisan Pennsylvania Bill Would Create Marijuana Regulatory Board Ahead Of Possible Adult-Use Legalization appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

TerrAscend Corp. has closed on its acquisition of Ratio Cannabis in Ohio and signed an agreement to acquire Union Chill Cannabis Co. in New Jersey. MSO TerrAscend acquires marijuana stores in Ohio, New Jersey is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Back MSO TerrAscend acquires marijuana stores in Ohio, New Jersey May 13, 2025 Margaret Jackson MJ Biz Daily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link TerrAscend Corp. has closed on its acquisition of Ratio Cannabis in Ohio and signed an agreement to acquire Union Chill Cannabis Co. in New Jersey. MSO TerrAscend acquires marijuana stores in Ohio, New Jersey is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The D.C. Council introduced a bill refining the medical cannabis regime by clarifying retail distance requirements near child-development facilities, broadening protest rights for Advisory Neighborhood Commissions and eligible parties, and aligning licensing criteria with enforcement considerations. A firm is prepared to advise operators, property owners, and community stakeholders on compliance obligations and strategic impacts related to these regulatory adjustments. < Back D.C. bill to clarify buffer zones between cannabis shops and early-childhood centers Dec 9, 2025 Editorial Staff Outlaw Report Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The D.C. Council has introduced a bill that would implement several notable refinements to the District’s medical cannabis regime. The proposed amendments clarify distance requirements for proposed retail locations near child-development facilities, broaden the scope of protest rights available to Advisory Neighborhood Commissions and eligible parties, and align licensing criteria with practical enforcement considerations identified by the Alcoholic Beverage and Cannabis Administration. As the District continues to adjust its regulatory framework, our firm is prepared to advise operators, property owners, and community stakeholders on compliance obligations and strategic impacts. Source < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5